[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study-Reference-Cited by-同舟云学术

[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Published:2018-06 Issue:6 Volume:19 Page:825-833
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hofman Michael S,Violet John,Hicks Rodney J,Ferdinandus Justin,Thang Sue Ping,Akhurst Tim,Iravani Amir,Kong Grace,Ravi Kumar Aravind,Murphy Declan G,Eu Peter,Jackson Price,Scalzo Mark,Williams Scott G,Sandhu Shahneen

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Increased survival with enzalutamide in prostate cancer after chemotreatment;Scher;N Engl J Med,2012

3. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

Cited by 880 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer;European Journal of Radiology;2024-11

2. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

3. Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma;EJNMMI Research;2024-09-12

4. Model-Informed Radiopharmaceutical Therapy Optimization: A Study on the Impact of PBPK Model Parameters on Physical, Biological, and Statistical Measures in 177Lu-PSMA Therapy;Cancers;2024-09-10

5. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-03